Pipeline-in-a-drug, page-79

Neuren is developing ground braking science in neurological disorders, a global leader in nerodevelpment therapy's.

Big Pharma globally have abandoned drugs in neurology to date with drugs affecting the nervous system having a 6% success rate.

Neuren has developed, 1 Phase 3 commercial asset in Rhetts, phase 2 Fragile x, and now in 2591 2 x phase 2's in PMS and PH, with a likely 3rd in Angleman to follow.. Strategy has now become clear because of this success to target additional single 5-8 other indications initially in mouse models to prove that 2591 is a platform drug or pipeline in a drug asset.

Neuren has had amazing success in phase 2's complimenting mouse models, I recall Jon saying a comment not that dissimilar after results in PMS not to dissimilar to Rhett, all they have to do in phase 3's is repeat phase 2 trial for a positive out come.

After all the failure in the industry globally in this space here we have 2591 a pipeline in a drug available to be purchased showing overwhelming results 2-3 indications maybe in phase 2's and mouse models in another 5-8 indications initially.

This story doesn't end with a TO for US$4bn, its almost laughable.

I think given the recent clarity shared by Jon suggesting pausing PW and rather now adding on additional indications to package this up if you like that this is now at least US$8.4bn or $100p/sh for Neu a starting point for a straight out TO.

I think our future inevitably is with Acadia and then packaged up with a TO for both, and this will take a bit more time to eventuate.